• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过反相微乳系统增强含有艾塞那肽的压力定量吸入器的稳定性。

Enhancing Stability of Exenatide-Containing Pressurized Metered-Dose Inhaler Via Reverse Microemulsion System.

机构信息

School of Pharmaceutical Sciences, Guangzhou Higher Education Mega Center, Sun Yat-sen University, No. 132, Waihuan East Road, 510006, Guangzhou, People's Republic of China.

College of Pharmacy, University of Texas at Austin, 2409 West University Avenue, PHR 1.108, Austin, Texas, 78712, USA.

出版信息

AAPS PharmSciTech. 2018 Aug;19(6):2499-2508. doi: 10.1208/s12249-018-1026-z. Epub 2018 Jun 11.

DOI:10.1208/s12249-018-1026-z
PMID:29948981
Abstract

The dispersibility and stability issues of peptide drugs during preparation and storage hinder the widespread adoption of pressurized metered-dose inhaler (pMDI). This study aimed to develop a reverse microemulsion (RM) of exenatide (EXE) pMDI through a liquid-based bottom-up method, thus to overcome the stability issue of peptide drugs encountered in traditional top-down methods, such as milling down and high-pressure homogenization. In this study, Pluronic® L64 (L64) was chosen as a surfactant to prepare the EXE-RM pMDI formulations with the assistance of ethanol. The results showed RM possessed a particle size of 123.80 ± 2.91 nm with 0.121 ± 0.024 PdI and a satisfied fine-particle fraction of 41.30 ± 3.73% measured by a next-generation impactor. In addition, the dispersion stability of RM pMDI was maintained after storage at 4 °C for 50 days. The secondary structure of EXE was maintained during the preparation process. Moreover, the results indicated that L64 was compatible with cells and could improve the penetration of EXE through cell monolayers. Through the liquid-based bottom-up method, EXE-RM pMDI was successfully prepared and exhibited favorable stability and aerodynamic performance. This study offers a preparation strategy to enhance the stability of peptides in pMDIs.

摘要

肽类药物在制备和储存过程中的分散性和稳定性问题阻碍了其在加压定量吸入器(pMDI)中的广泛应用。本研究旨在通过基于液体的自下而上的方法开发一种艾塞那肽(EXE)pMDI 的反胶束(RM),从而克服传统自上而下方法(如研磨和高压匀浆)中遇到的肽类药物稳定性问题。在本研究中,选择 Pluronic® L64(L64)作为表面活性剂,在乙醇的辅助下制备 EXE-RM pMDI 制剂。结果表明,RM 的粒径为 123.80±2.91nm,多分散指数(PdI)为 0.121±0.024,下一代撞击器测量的细颗粒分数为 41.30±3.73%。此外,RM pMDI 在 4°C 储存 50 天后仍能保持分散稳定性。EXE 的二级结构在制备过程中得以保持。此外,结果表明 L64 与细胞相容,并能提高 EXE 通过细胞单层的渗透。通过基于液体的自下而上的方法,成功制备了 EXE-RM pMDI,表现出良好的稳定性和空气动力学性能。本研究为提高 pMDI 中肽类药物的稳定性提供了一种制备策略。

相似文献

1
Enhancing Stability of Exenatide-Containing Pressurized Metered-Dose Inhaler Via Reverse Microemulsion System.通过反相微乳系统增强含有艾塞那肽的压力定量吸入器的稳定性。
AAPS PharmSciTech. 2018 Aug;19(6):2499-2508. doi: 10.1208/s12249-018-1026-z. Epub 2018 Jun 11.
2
Anhydrous reverse micelle nanoparticles: new strategy to overcome sedimentation instability of peptide-containing pressurized metered-dose inhalers.无水反胶束纳米颗粒:克服含肽类压力定量吸入器沉降不稳定性的新策略。
Drug Deliv. 2017 Nov;24(1):527-538. doi: 10.1080/10717544.2016.1269850.
3
Variability in Delivered Dose from Pressurized Metered-Dose Inhaler Formulations Due to a Delay Between Shake and Fire.由于摇晃与喷射之间的延迟导致的定量压力气雾剂剂型给药剂量的变异性。
J Aerosol Med Pulm Drug Deliv. 2017 Feb;30(1):71-79. doi: 10.1089/jamp.2015.1284. Epub 2016 Sep 16.
4
Formulation and evaluation of novel reverse microemulsions containing salmon calcitonin in hydrofluoroalkane propellants.新型鲑鱼降钙素反胶束在含氟烷烃推进剂中的配方与评价。
Int J Pharm. 2014 May 15;466(1-2):390-9. doi: 10.1016/j.ijpharm.2014.03.032. Epub 2014 Mar 20.
5
Development of a self-microemulsifying drug delivery system to deliver delamanid via a pressurized metered dose inhaler for treatment of multi-drug resistant pulmonary tuberculosis.开发一种自微乳化药物递送系统,通过定量压力吸入器递送地拉曼尼,用于治疗耐多药肺结核。
Int J Pharm. 2024 Apr 25;655:124031. doi: 10.1016/j.ijpharm.2024.124031. Epub 2024 Mar 21.
6
Optimizing the primary particle size distributions of pressurized metered dose inhalers by using inkjet spray drying for targeting desired regions of the lungs.通过使用喷墨喷雾干燥技术优化压力定量吸入器的初级粒径分布,以靶向肺部的期望区域。
Drug Dev Ind Pharm. 2015 Feb;41(2):279-91. doi: 10.3109/03639045.2013.858741. Epub 2013 Nov 19.
7
Development of Aggregation-Caused Quenching Probe-Loaded Pressurized Metered-Dose Inhalers with Fluorescence Tracking Potentials.利用荧光追踪潜力开发具有聚集猝灭探针负载的加压计量吸入器。
AAPS PharmSciTech. 2020 Oct 25;21(8):296. doi: 10.1208/s12249-020-01782-1.
8
Co-suspension delivery technology in pressurized metered-dose inhalers for multi-drug dosing in the treatment of respiratory diseases.加压定量吸入器中共混悬液递送技术在呼吸道疾病多药物给药治疗中的应用。
Respir Med. 2018 Jan;134:16-23. doi: 10.1016/j.rmed.2017.09.012. Epub 2017 Sep 25.
9
The influence of initial atomized droplet size on residual particle size from pressurized metered dose inhalers.雾化初始液滴大小对压力定量吸入器残留颗粒大小的影响。
Int J Pharm. 2013 Oct 15;455(1-2):57-65. doi: 10.1016/j.ijpharm.2013.07.061. Epub 2013 Aug 1.
10
In vitro characterization of the OptiChamber Diamond valved holding chamber.OptiChamber Diamond 瓣阀储雾器的体外特性研究。
J Aerosol Med Pulm Drug Deliv. 2014 Aug;27 Suppl 1:S24-36. doi: 10.1089/jamp.2013.1067.

引用本文的文献

1
A Pilot Study Exploiting the Industrialization Potential of Solid Lipid Nanoparticle-Based Metered-Dose Inhalers.一项探索基于固体脂质纳米粒的定量吸入器产业化潜力的初步研究。
Pharmaceutics. 2023 Mar 7;15(3):866. doi: 10.3390/pharmaceutics15030866.
2
Low Drug Loading Hampers the Clinical Translation of Peptide Drugs-Containing Metered-Dose Inhalers.低载药量阻碍了含肽药物的定量吸入器的临床转化。
Pharmaceuticals (Basel). 2022 Mar 23;15(4):389. doi: 10.3390/ph15040389.
3
Comparison of ELISA and HPLC-MS methods for the determination of exenatide in biological and biotechnology-based formulation matrices.
酶联免疫吸附测定法(ELISA)与高效液相色谱-质谱联用(HPLC-MS)法在生物制剂和基于生物技术的制剂基质中测定艾塞那肽的比较。
J Pharm Anal. 2019 Jun;9(3):143-155. doi: 10.1016/j.jpha.2019.02.001. Epub 2019 Feb 26.
4
Drying Technologies for the Stability and Bioavailability of Biopharmaceuticals.用于生物制药稳定性和生物利用度的干燥技术
Pharmaceutics. 2018 Aug 17;10(3):131. doi: 10.3390/pharmaceutics10030131.